Funding as declared in published cost-effectiveness analyses: acknowledgements/grants/affiliations
| Funding source as stated | |||
|---|---|---|---|
| Author, PYR | Acknowledgement (trial data, or not specified) | Grant | (Co-)Authors' affiliation, or ‘editorial assistance’, if other than academic institution/university/hospital |
| Bansback et al 200541 | Abbott | Abbott: editorial assistance | |
| Barbieri et al 200547 | Schering-Plough (research grant) | Schering-Plough | – |
| Brennan et al 200445 | Wyeth | ||
| Brennan et al 200739 | Grant from the British Society for Rheumatology (BSR receives support from Abbott, Amgen, Schering-Plough, and Wyeth) | ||
| Chen et al200628 | Author previously received funding from Abbott and Wyeth | Funded by the HTA Programme on behalf of NICE | – |
| Chiou et al 200442 | Cerner Corporation | ||
| Choi et al200055 | ‘No specific source of support’ | – | |
| Choi et al 200220 | ‘No specific financial support’ | – | |
| Clark et al 200456 | HTA | – | |
| Davies et al 200932 | Abbott | Emron, Abbott, JK Associates, Inc.: editorial assistance | |
| Fautrel et al 200830 31 AB | NS (AB) | ||
| Finckh et al 200921 | Arthritis foundation, anonymous donor | ||
| Gdovin Bergeson and Rosenblatt59 AB | Bristol-Myers Squibb | ||
| Jobanputra et al 200252 | Author engaged in a Wyeth-sponsored trial | NHS/HTA (Commissioned by HTA Programme on behalf of NICE) | – |
| Kielhorn et al 200860 | Hoffmann-La Roche | Hoffmann-La Roche | |
| Kobelt et al 200215 | NS | Stockholm Health Economics Consulting | |
| Kobelt et al 200348 | Schering-Plough | – | |
| Kobelt et al 200444 | Österlund/Kock Foundation, King Gustav V Fund, Reumatikerförbundet | – | |
| Kobelt et al 200543 | Wyeth | Wyeth | |
| Maetzel et al 200237 | Author consultant to Aventis | Aventis | |
| Marra et al 200746 | Canadian Arthritis Network | – | |
| Payet 200761 77 | NS (AB) | Hoffmann-La Roche77 | |
| Pompen et al 200762 | Hoffmann-La Roche | ||
| Russell et al 200966 | Bristol-Myers Squibb | ||
| Schädlich et al 200514 | Aventis | Aventis | |
| Spalding and Hay 200629 | Abbott (‘previously’) | Astellas Pharma | |
| Vera-Llonch et al 200857 | Bristol-Myers Squibb | Bristol-Myers Squibb | |
| Vera-Llonch et al 200865 | Bristol-Myers Squibb | Bristol-Myers Squibb | |
| Welsing et al 200436 | Wyeth trial data | ||
| Wailoo et al 200840 | NS | – | |
| Wong et al 200249 | Schering-Plough | ||
| Yuan et al 200864 AB | Bristol-Myers Squibb | ||
AB, published in abstract form only; HTA, Health Technology Assessment Report; NICE, National Institute for Health and Clinical Excellence; NS, not stated; PYR, year of publication.